MX383792B - Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. - Google Patents

Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.

Info

Publication number
MX383792B
MX383792B MX2017003436A MX2017003436A MX383792B MX 383792 B MX383792 B MX 383792B MX 2017003436 A MX2017003436 A MX 2017003436A MX 2017003436 A MX2017003436 A MX 2017003436A MX 383792 B MX383792 B MX 383792B
Authority
MX
Mexico
Prior art keywords
eye
protection
drug administration
anterior segment
compound
Prior art date
Application number
MX2017003436A
Other languages
English (en)
Spanish (es)
Other versions
MX2017003436A (es
Inventor
Paul G Chaney
David P Bingaman
Martin B Wax
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of MX2017003436A publication Critical patent/MX2017003436A/es
Publication of MX383792B publication Critical patent/MX383792B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017003436A 2014-09-17 2015-09-17 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. MX383792B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051794P 2014-09-17 2014-09-17
PCT/US2015/050818 WO2016044671A1 (en) 2014-09-17 2015-09-17 Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Publications (2)

Publication Number Publication Date
MX2017003436A MX2017003436A (es) 2017-07-28
MX383792B true MX383792B (es) 2025-03-14

Family

ID=55453708

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003436A MX383792B (es) 2014-09-17 2015-09-17 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
MX2021006070A MX2021006070A (es) 2014-09-17 2017-03-15 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006070A MX2021006070A (es) 2014-09-17 2017-03-15 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.

Country Status (19)

Country Link
US (6) US9814702B2 (enExample)
EP (2) EP3878449B1 (enExample)
JP (3) JP6657193B2 (enExample)
KR (2) KR102450020B1 (enExample)
CN (2) CN113209000B (enExample)
AU (2) AU2015317531B2 (enExample)
CA (1) CA2958315A1 (enExample)
DK (1) DK3193867T3 (enExample)
ES (2) ES3010497T3 (enExample)
HU (1) HUE053852T2 (enExample)
IL (2) IL282504B (enExample)
MA (1) MA56220A (enExample)
MX (2) MX383792B (enExample)
NZ (1) NZ767710A (enExample)
PL (1) PL3193867T3 (enExample)
PT (1) PT3193867T (enExample)
RU (2) RU2704810C2 (enExample)
WO (1) WO2016044671A1 (enExample)
ZA (1) ZA201701303B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil
SG11201907400YA (en) * 2018-07-18 2020-02-27 Univ Wenzhou Medical Method for treating myopia and application in preparation of medicament
EP3870204A4 (en) * 2018-10-24 2022-12-21 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics formulations
JP2022131565A (ja) * 2021-02-26 2022-09-07 ロート製薬株式会社 水性医薬組成物
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053806A1 (en) * 1997-05-26 1998-12-03 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
YU36403A (sh) * 2000-11-28 2006-08-17 Pfizer Products Inc. Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007041499A2 (en) * 2005-09-30 2007-04-12 Lipoprotein Technologies, Inc. Cox inhibitor and nicotinic acid compositions and methods
WO2009129859A1 (en) * 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
RU2012105453A (ru) 2009-08-11 2013-09-20 Аллерган, Инк. Изотиозолы для лечения состояний глаз
EP2482677A1 (en) * 2009-09-30 2012-08-08 The Regents of The University of California Cofactors and methods for use for individuals
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP5956992B2 (ja) * 2010-08-17 2016-07-27 オーエイチアール・ファーマシューティカル・インコーポレイテッドOhr Pharmaceutical,Inc. スクアラミンの眼用製剤
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012162627A1 (en) * 2011-05-26 2012-11-29 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
JP6363506B2 (ja) * 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンa2型の懸濁剤
CA2865132A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
SG11201507316UA (en) * 2013-03-14 2015-10-29 Panoptica Inc Ocular formulations for drug-delivery to the posterior segment of the eye
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil

Also Published As

Publication number Publication date
PT3193867T (pt) 2021-03-09
JP6657193B2 (ja) 2020-03-04
RU2017112930A (ru) 2018-10-17
KR102450020B1 (ko) 2022-09-30
CA2958315A1 (en) 2016-03-24
EP3193867A1 (en) 2017-07-26
ES3010497T3 (en) 2025-04-03
IL282504B (en) 2022-08-01
EP3193867A4 (en) 2018-05-02
MX2017003436A (es) 2017-07-28
US20160206599A1 (en) 2016-07-21
BR112017005523A2 (pt) 2017-12-05
CN113209000A (zh) 2021-08-06
MA56220A (fr) 2022-04-20
IL282504A (en) 2021-06-30
JP2021121624A (ja) 2021-08-26
ES2863601T3 (es) 2021-10-11
HUE053852T2 (hu) 2021-07-28
US20210275501A1 (en) 2021-09-09
DK3193867T3 (da) 2021-04-06
US20190314343A1 (en) 2019-10-17
PL3193867T3 (pl) 2021-07-12
RU2017112930A3 (enExample) 2019-04-11
KR20220137157A (ko) 2022-10-11
EP3878449A1 (en) 2021-09-15
US9814702B2 (en) 2017-11-14
AU2015317531A1 (en) 2017-03-09
AU2021200997B2 (en) 2023-02-02
JP7176042B2 (ja) 2022-11-21
JP2020079274A (ja) 2020-05-28
MX2021006070A (es) 2021-07-06
WO2016044671A1 (en) 2016-03-24
JP2017527600A (ja) 2017-09-21
AU2015317531B2 (en) 2020-11-19
CN113209000B (zh) 2025-05-13
JP6890692B2 (ja) 2021-06-18
AU2021200997A1 (en) 2021-03-11
US10183014B2 (en) 2019-01-22
US20160074371A1 (en) 2016-03-17
IL251019B (en) 2021-05-31
US20240277674A1 (en) 2024-08-22
IL251019A0 (en) 2017-04-30
RU2704810C2 (ru) 2019-10-31
ZA201701303B (en) 2021-07-28
EP3193867B1 (en) 2021-01-20
US9623011B2 (en) 2017-04-18
NZ729142A (en) 2023-08-25
RU2768652C1 (ru) 2022-03-24
KR102555091B1 (ko) 2023-07-13
CN106999476A (zh) 2017-08-01
US20180078531A1 (en) 2018-03-22
NZ767710A (en) 2023-09-29
CN106999476B (zh) 2021-05-04
EP3878449B1 (en) 2024-10-30
KR20170058976A (ko) 2017-05-29

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
MX2015013396A (es) Derivados de quinolinas como nuevos agentes contra el cancer.
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12016500582B1 (en) Heterocyclic compounds and uses thereof
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
EA201892415A1 (ru) Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MY199091A (en) Therapeutic compounds
EP3334719A4 (en) SUBSTITUTED BENZIMIDAZOLE, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
PH12019500024A1 (en) Pharmaceutical compositions
GT201600072A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
EP3187179A4 (en) Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient
CR20160177A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)1h-pirazol-5-olato de sodio